LGND

Business Context and Reporting Period

Ligand Pharmaceuticals Inc. filed its Form 10-Q for the quarterly period ended September 30, 2001. The company develops and markets drugs for cancer, men's and women's health, skin diseases, and osteoporosis. Key marketed products include Panretin, Targretin, and ONTAK (via subsidiary Seragen). The company has been unprofitable since inception and relies on product sales and collaborative research agreements for revenue.

Key Financial Metrics

Note: Balance sheet figures represent the position as of September 30, 2001, compared to December 31, 2000 where applicable.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 41% ($5.6 million) for the quarter and 57% ($19.4 million) for the nine months compared to the prior year periods. Product sales rose significantly, driven by a 124% increase in ONTAK sales and a 36% increase in Targretin capsules sales for the quarter.
• Improved Loss Position: Net loss decreased by $5.7 million for the quarter and $29.7 million for the nine months compared to the prior year. The prior year 2000 results included a one-time cumulative effect of a change in accounting principle (SAB No. 101) of $13.1 million.
• Expense Management: Research and development expenses decreased slightly for the quarter ($12.9 million vs. $13.2 million) but remained flat for the nine months ($38.5 million). Selling, general, and administrative (SG&A) expenses decreased for the quarter due to lower advertising costs, though they increased slightly for the nine months due to sales force expansion.
• Liquidity: Working capital improved from $16.2 million at year-end 2000 to $27.0 million at September 30, 2001. Cash and cash equivalents increased from $9.2 million to $17.8 million.

Guidance, Outlook, and Risks

Outlook and Commentary: Management expects to incur substantial additional operating losses until product sales cover expenses. The company anticipates launching Panretin gel and Targretin capsules in Europe in the fourth quarter of 2001. They believe current cash, investments, and funding sources are adequate for at least the next 12 months.

Collaborations: New agreements were signed with TAP Pharmaceutical Products Inc. (SARMs research). Conversely, Bristol-Myers Squibb terminated its mineralocorticoid receptor collaboration in June 2001.

Risks and Contingencies:

• Debt Obligations: The company has significant debt, including $50 million in convertible subordinated debentures (due 2003), $84.6 million in zero-coupon convertible senior notes to Elan (due 2008), and a $2.5 million note to GlaxoSmithKline. Failure to make payments could trigger defaults.
• Regulatory and Development: Success depends on FDA approvals for products like Morphelan (partner Elan) and new indications. Clinical trials carry risks of failure or delay.
• Patent Disputes: The company is involved in a patent interference proceeding with Hoffmann-La Roche regarding Panretin, which could impact future sales if the company does not prevail.
• Capital Needs: The company may require additional equity or debt financing, which could result in dilution to existing shareholders.

Investor Verification Checklist

• Debt Maturity Profile: Verify the ability to service the $50 million Glycomed debentures due in 2003 and the $84.6 million Elan notes.
• Product Sales Trajectory: Confirm the sustainability of the 124% growth in ONTAK sales and the impact of European launches on Q4 2001 revenue.
• Patent Litigation Status: Monitor the outcome of the patent interference proceeding with Hoffmann-La Roche regarding Panretin.
• Cash Burn Rate: Assess whether the $16.4 million net cash used in operating activities for the nine months is sustainable given the current cash balance of $17.8 million.
• Collaboration Milestones: Track the status of the Morphelan NDA with Elan and the potential $5 million milestone payment obligation.